The company has decided to partially change its current sales strategy to invest more in direct sales resources in its key markets in the US and France. One consequence of this is that the company now forms its own subsidiary in France and employs its own sales resources. The recruitment of additional salespeople in the US has also just begun. In addition to investing in our own sales resources, further focus will be placed on seeking collaborations with strategic partners in the North American market as well. To relieve the CEO, a CFO will be hired. One consequence of the changed strategy is that the current sales manager leaves the company on April 30.

Mats Högberg, CEO, comments: "After analysis, we have decided to focus more on the markets where we have important reference installations, and which also have the greatest potential. That is why we form our own company in France and employ our own sales resources. In the US, we have just initiated the recruitment of another salesperson with a location on the East Coast. In combination with the investment in our own sales resources in key markets, we will focus further on establishing strategic partnerships with major players in the industry. The interest in our technology is strong and our solutions fit well into several of the larger companies' more comprehensive solutions for more efficient and safer drug management."